11/15
06:04 pm
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
Low
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
11/15
08:35 am
cgtx
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
High
Report
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
11/13
07:30 am
cgtx
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
Medium
Report
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update
11/12
07:30 am
cgtx
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
High
Report
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum
11/4
08:19 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/31
04:15 pm
cgtx
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
Low
Report
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
10/31
10:42 am
cgtx
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
Low
Report
Cognition Therapeutics, Inc. (NASDAQ: CGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $11.00 price target on the stock.
10/29
12:55 pm
cgtx
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
Low
Report
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
10/23
07:30 am
cgtx
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
High
Report
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
10/22
07:30 am
cgtx
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
Low
Report
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
10/2
07:30 am
cgtx
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
Low
Report
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
10/1
07:30 am
cgtx
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
Medium
Report
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
9/3
07:30 am
cgtx
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
Medium
Report
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences